Navigation Links
Pulmonx Announces New President and CEO Michael A. Baker to Lead Interventional Pulmonology Company
Date:7/15/2009

REDWOOD CITY, Calif., July 15 /PRNewswire/ -- Pulmonx, an emerging leader in interventional pulmonology and in the development of device therapies for the treatment of emphysema announced today that Michael A. Baker has joined the company as President and CEO and that he has been elected as a member of its board of directors.

"We are very excited that Mike will be leading our company as we begin to commercialize our proprietary medical device therapies for these important indications," said Dr. Rodney Perkins, Founder and Chairman of the Board. "The strategic and leadership skills he has developed over the course of his career will be of great value to Pulmonx."

Mr. Baker's professional career comprises over two decades of executive experience in the medical device industry with much of it directly focused on the development and commercialization of new device technologies and device-based therapies. His career includes assignments with ArthroCare Corporation, where he served as the President and CEO for over 11 years, and with Medtronic, where he served for over 8 years in executive and general management assignments in both the United States and Europe. Mr. Baker holds an M.B.A. from the University of Chicago and a B.S. from the United States Military Academy at West Point.

The addition of Mike Baker follows a series of strategic developments including the receipt of FDA marketing clearance for a key new product and the completion of a successful acquisition. In early July, the company received FDA marketing clearance for the Chartis System, an assessment tool which allows physicians to make regional assessments of lung function, including quantifying inter-lobar airflow in the lungs, known as collateral ventilation. Recent research suggests that the presence of collateral ventilation may have an important impact on the effectiveness of Endobronchial Lung Volume Reduction (ELVR) therapy(1, 2). By helping physicians to identify the presence of collateral ventilation, the Chartis System may enable them to better identify patients who could benefit from endobronchial valve therapy.

The FDA clearance follows Pulmonx's recent acquisition of Emphasys Medical, which added Emphasys' Zephyr family of endobronchial valves for ELVR to the company's proprietary portfolio of diagnostic and therapeutic products. The Zephyr endobronchial valves are already CE marked and commercially available in many countries around the world. Pulmonx intends to begin international commercialization of the Chartis system as soon as it receives the CE mark.

"This is an exciting time for all of us here at Pulmonx," commented Mike Baker, President and CEO of Pulmonx. "With the completion of the acquisition of Emphasys Medical, Inc. and 510K clearance of our Chartis System, Pulmonx is poised to become a leader in the treatment of pulmonary disorders such as severe emphysema. These new technologies have the potential to cost-effectively improve the health of literally millions of patients globally and I'm extremely enthusiastic about the opportunity to lead this outstanding team as we work to commercialize these breakthrough products and build a strong franchise in Interventional Pulmonology."

About Pulmonx

Pulmonx Corporation, based in Redwood City, Calif., is focused on developing and marketing minimally-invasive medical devices and technologies for the diagnosis and treatment of pulmonary disorders. Pulmonx is venture funded by Montreux Ventures, MedVenture Associates, DeNovo Ventures, Latterell Ventures, Covidien Ventures and Posco Bioventures.

(1) Aljuri N, Freitag L. Validation and pilot clinical study of a new bronchoscopic method to measure collateral ventilation prior to endobronchial lung volume reduction. J Appl Physiol. 2009;106:774-783.

(2) Fessler HE. Collateral damage assessment for endobronchial lung volume reduction. J Appl Physiol. 2009;106:755-756.


'/>"/>
SOURCE Pulmonx Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pulmonx Acquires Assets of Emphasys Medical and Unveils Combined Product Portfolio at International Conference of the American Thoracic Society (ATS) Annual Meeting
2. VA Announces $26 Million Construction Contract for Palo Alto
3. ResMed Announces Conference Call and Webcast to Discuss Fourth Quarter and Fiscal Year End 2009 Results
4. CorVel Announces Earnings Release Webcast
5. Wyeth Announces Results of the Companys Offer Relating to Holder Right to Surrender Convertible Debentures
6. Wonderbox Technologies(R) Announces 2nd Annual Super User of the Year
7. Kendle Announces Details Regarding Second Quarter 2009 Earnings Conference Call and Webcast
8. Bayer HealthCare Announces Recipients of 2009 International Hemophilia Nursing Fellowship
9. Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance(TM) for Treatment of Acute Pain and Fever
10. Snoring Isn't Sexy, LLC Announces Professional Relationship with the American Sleep Apnea Association
11. Management Health Solutions, Inc. Announces Optimal Inventory Control™ (OptIC™) Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
(Date:6/24/2016)... ... 24, 2016 , ... EB Medicine presented its first-ever “Issue ... conference in Ponte Vedra Beach, FL. The awards honor the outstanding work of ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- Dublin ... the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global market ... its applications in various applications. The report deals with ... main industries: pharmaceutical and biotechnology, food and beverage, and ...
(Date:6/24/2016)... Calif. , June 24, 2016  American Respiratory Labs (ARL), ... is now able to perform sophisticated lung assessments in patients, homes, ... , Inc. Patients are no longer limited to ... EasyOne PRO ® , ARL patients like Jeanne R. of ... in the comfort of her own home. ...
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
Breaking Medicine Technology: